Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis

Hepatology Research

Volumn 40, Issue 10, 2010, Pages 943-953

  Zhong, Jian Hong ^a   Li, Le Qun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Lipiodol; Meta analysis; Postoperative; Transarterial chemoembolization

Indexed keywords

ADRIAMYCINONE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GELATIN SPONGE; IODINATED POPPYSEED OIL; MITOMYCIN;

ADJUVANT THERAPY; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; FATIGUE; FEVER; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; POSTOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

EID: 77957242266     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00710.x     Document Type: Article

References (65)

1. Mortality database. http://www.who.int/whosis/en, World Health Organization, [Cited 20 Oct 2009.] Available from URL:
2. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143-54.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
4. Butler JR, Pianko S, Korda RJ. The direct cost of managing patients with chronic hepatitis B infection in Australia. J Clin Gastroenterol 2004, 38:187-92.
5. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005, 11:7391-400.
6. Makuuchi M, Donadon M, Torzilli G. Hepatic resection for hepatocellular carcinoma in cirrhosis. Ann Ital Chir 2008, 79:111-5.
7. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35:519-24.
8. Arii S, Yamaoka Y, Futagawa S. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000, 32:1224-9.
9. Lang H, Sotiropoulos GC, Brokalaki EI. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007, 205:27-36.
10. Dupont-Bierre E, Compagnon P, Raoul JL, Fayet G, de Lajarte-Thirouard AS, Boudjema K. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005, 201:663-70.
11. Capussotti L, Muratore A, Amisano M, Polastri R, Bouzari H, Massucco P. Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival - a European single center experience. Eur J Surg Oncol 2005, 31:986-93.
12. Imamura H, Matsuyama Y, Tanaka E. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-7.
13. Shen BY, Li HW, Regimbeau JM, Belghiti J. Recurrence after resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002, 1:401-5.
14. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon 2005, 3:210-5.
15. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-17.
16. Cheng HY, Wang X, Chen D, Xu AM, Jia YC. The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. World J Gastroenterol 2005, 11:3644-6.
17. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998, 133:183-8.
18. Ueno S, Tanabe G, Yoshida A, Yoshidome S, Takao S, Aikou T. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999, 86:248-54.
19. Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008, 247:43-8.
20. Boucher E, Corbinais S, Rolland Y. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003, 38:1237-41.
21. Takayama T, Sekine T, Makuuchi M. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356:802-7.
22. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002, 89:418-22.
23. Sun HC, Tang ZY, Wang L. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006, 132:458-65.
24. Peng BG, Liang LJ, He Q. Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 2005, 11:700-4.
25. Muto Y, Moriwaki H, Ninomiya M. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996, 334:1561-7.
26. Toyoda H, Nakano S, Kumada T. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995, 52:295-9.
27. Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 2006, 202:155-68.
28. Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990, 66:1897-903.
29. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002, 13:211-21.
30. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009, 10:425-34.
31. Timm S, Sotiropoulos GC, Draier M, Knupffer J, Steger U, Lang H. Selective transarterial chemoembolization of advanced hepatocellular carcinomas: a reasonable palliative option. Transplant Proc 2008, 40:3179-81.
32. Camma C, Schepis F, Orlando A. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224:47-54.
33. Ramsey DE, Geschwind JF. Chemoembolization of hepatocellular carcinoma - what to tell the skeptics: review and meta-analysis. Tech Vasc Interv Radiol 2002, 5:122-6.
34. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-42.
35. Ren ZG, Lin ZY, Xia JL. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 2004, 10:2791-4.
36. Liu Y, Yang R. Preoperative combined with postoperative chemoembolization can improve survival in patients with hepatocellular carcinoma: a single-center study. J Vasc Interv Radiol 2009, 20:472-83.
37. Shuqun C, Mengchao W, Han C. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology 2004, 51:1445-7.
38. Shimoda M, Bando T, Nagata T, Shirosaki I, Sakamoto T, Tsukada K. Prophylactic chemolipiodolization for postoperative hepatoma patients. Hepatogastroenterology 2001, 48:493-7.
39. Izumi R, Shimizu K, Iyobe T. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994, 20:295-301.
40. Li JQ, Zhang YQ, Zhang WZ, Yuan YF, Li GH. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 1995, 121:364-6.
41. Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 2009, 198:313-8.
42. Zhong C, Guo RP, Li JQ. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 2009, 135:1437-45.
43. Li Q, Wang J, Sun Y. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig Surg 2006, 23:235-40.
44. Yu ZP, Xu ZK, Zhou WZ, Hu WH, Yu C, QQ Z. The efficacy of transarterial chemoembolization for hepatocellular carcinoma after curative resection. J Pract Med 2009, 25:1819-21.
45. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002, 3:593-603.
46. Mathurin P, Raynard B, Dharancy S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther 2003, 17:1247-61.
47. Marelli L, Stigliano R, Triantos C. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006, 32:594-606.
48. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009, (1):CD001199.
49. Lau WY, Lai EC, Lau SH. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2009, 8:124-33.
50. Wu TX, Liu GJ. The concepts, design, practice and report of allocation concealment and blinding. Chin J Evid Based Med 2007, 7:219-22.
51. Li Q, Wang J, Sun Y. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis - a randomized study. World J Surg 2006, 30:2004-11.
52. Zhong C, Guo RP, Chen MS, Wei W, Chen ZY. Efficacy of hepatectomy-predominant treatment on stage IIIA hepatocellular carcinoma: a report of 108 cases. Chin J Cancer 2009, 28:230-3.
53. Cheng SQ, Wu MC, Chen H. Transcatheter hepatic arterial chemoembolization and thymosin alpha1 in postoperative treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2004, 26:305-7.
54. Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication. J Hepatol 2000, 33:1006-8.
55. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89:500-7.
56. Takenaka K, Yoshida K, Nishizaki T. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg 1995, 169:400-4.
57. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - a literature review of randomized control trials. World J Gastroenterol 2003, 9:635-40.
58. Tanaka K, Shimada H, Togo S. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 1999, 46:1083-8.
59. Nonami T, Isshiki K, Katoh H. The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas. Ann Surg 1991, 213:222-6.
60. Lu X, Zhao H, Yang H. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy. J Surg Oncol 2009, 100:488-93.
61. Jaeger HJ, Mehring UM, Castaneda F. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol 1996, 19:388-96.
62. Yamashita Y, Torashima M, Oguni T. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation. Abdom Imaging 1993, 18:352-6.
63. Kwok PC, Lam TW, Lam PW. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. J Gastroenterol Hepatol 2003, 18:450-5.
64. Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer 2009, 124:2982-8.
65. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009, 96:975-81.